Delving into the Latest Updates on Beijing Jiufangyuan Health Products Distribution Co., Ltd. with Synapse

Overview

Tags

Respiratory Diseases

Neoplasms

Herbal medicine

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Neoplasms	1

Top 5 Drug Type	Count

Herbal medicine	1

采用随机双盲的方法以Ⅲ、Ⅳ期非小细胞肺癌患者为研究对象，用灵芝扶正颗粒对非小细胞肺癌完成化疗患者，口服灵芝扶正颗粒3个月并进行6个月的临床观察，旨在明确该药： 1.能否提高患者免疫功能，降低复发转移率； 2.能否延长患者无进展生存期； 3.能否提高患者的生活质量； 4.是否有重大不良作用.

[Translation]

A randomized double-blind method was used to study patients with stage III and IV non-small cell lung cancer. Lingzhi Fuzheng Granules were used to treat patients who had completed chemotherapy for non-small cell lung cancer. The patients took Lingzhi Fuzheng Granules orally for 3 months and underwent clinical observation for 6 months. The purpose was to determine whether the drug: 1. Can it improve the patient's immune function and reduce the recurrence and metastasis rate; 2. Can it prolong the patient's progression-free survival; 3. Can it improve the patient's quality of life; 4. Whether it has major adverse effects.

Start Date-

Sponsor / Collaborator

Shenyang Wanjia Biologic Technology Research Institute

[+1]

100 Clinical Results associated with Beijing Jiufangyuan Health Products Distribution Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Beijing Jiufangyuan Health Products Distribution Co., Ltd.

Login to view more data

100 Deals associated with Beijing Jiufangyuan Health Products Distribution Co., Ltd.

Login to view more data

100 Translational Medicine associated with Beijing Jiufangyuan Health Products Distribution Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 10 Jun 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

1

Login to view more data